Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Prices IPO at $10 per Share

NEW YORK (GenomeWeb News) – NanoString Technologies late on Tuesday priced its planned initial public offering at $10 per share.

The company expects to offer 5.4 million shares of its common stock in the offering. In a prospectus filed today, NanoString said that it anticipates net proceeds from the offering of about $50.2 million.

Additionally, it has granted the underwriters a 30-day option to purchase up to 810,000 shares to cover any over-allotments.

JP Morgan and Morgan Stanley are the book-running managers, while Leerink Swann and RW Baird are co-managers. NanoString plans to trade on the Nasdaq Global Market under ticker symbol "NSTG".

Seattle-based NanoString announced its plans to go public a month ago with a proposed maximum aggregate offering price of about $86.3 million. Two weeks ago, it said that the share price on the offering was expected to be between $13 and $15, which would have brought in as much as $77.6 million.

The firm said that it would use proceeds from the offering to commercialize its Prosigna Breast Cancer Assay after receiving US regulatory authorization, including the creation of a dedicated oncology sales force; support and grow the installed base of its nCounter molecular analysis systems among life science research customers; and develop new life sciences applications, chemistry, and instrumentation for the nCounter platform.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.